You just read:

Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

News provided by

Eli Lilly and Company

May 15, 2018, 06:45 ET